Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported financial results for the first half of 2026, revealing a 23% increase in revenue and significant strides in an expanded U.S. clinical manufacturing program. The biopharmaceutical company, which combines therapeutic development with a contract development and manufacturing organization (CDMO), is positioning itself to capitalize on the growing demand for specialized biopharmaceutical services.
For the six months ended June 30, 2026, Scinai recorded revenue of $949,000, up from $773,000 in the same period last year. Committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including about $2.1 million already invoiced. This robust order book underscores the company’s ability to attract and retain clients for its CDMO services.
The company is also advancing an expanded clinical manufacturing and chemistry, manufacturing, and controls (CMC) program for a U.S.-based biopharmaceutical company. Scinai has received approximately $650,000 in cash payments and advances, with substantive activities already underway. While a definitive agreement is still under negotiation, the program is intended to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. This initiative could significantly bolster Scinai’s revenue stream and enhance its reputation in the industry.
Scinai continues to pursue approximately $5 million in CDMO revenue for 2026, a target that would represent a substantial increase over current levels. The company’s CDMO subsidiary, Scinai Biopharma Services Ltd., provides development and manufacturing services to biotech and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
Financially, Scinai reported an operating loss of approximately $4.6 million for the first half, compared with $3.8 million a year earlier. However, net income was approximately $1.6 million, a significant turnaround from a net loss of approximately $4.1 million in the prior-year period. This improvement was primarily due to a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. Cash, cash equivalents, and restricted cash totaled approximately $2.9 million as of June 30, 2026.
The company continues to advance its PC111 and NanoAbs therapeutic programs, which are part of its pipeline of innovative immunology therapies licensed from the Max Planck Society and PinCell S.r.l. These programs hold promise for addressing unmet medical needs in immunology.
Scinai will host an investor webinar on Aug. 26, 2026, to discuss recent developments, financial performance, and upcoming milestones. This webinar provides an opportunity for investors to gain deeper insights into the company’s strategies and growth prospects.
The importance of Scinai’s recent progress lies in its dual business model. By leveraging its CDMO services to generate revenue while advancing its own therapeutic pipeline, the company aims to create a sustainable financial foundation. The expansion of its U.S. clinical manufacturing program could open doors to larger contracts and strategic partnerships, potentially transforming its revenue profile.
For more details, visit the full press release at https://nnw.fm/Be7Ky.
